Update on commercialisation of PromarkerD in the USA
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This allows Proteomics International to pursue alternative licensing options and direct consumer sales for PromarkerD in the US market. The PromarkerD assay has been established in a CLIA certified laboratory in the USA, preparing for its launch.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Groundbreaking results for type 1 diabetes and kidney health
- June 2024 Quarterly Activities Report and Appendix 4C
- Eurobio Scientific to sell PromarkerD DKD test in France
- Proteomics appoints medical devices sales agency for Europe
- March 2024 Quarterly Activities Report and Appendix 4C
Later from Proteomics International Laboratories
- Esophageal cancer diagnostic delivers excellent results
- September 2024 Quarterly Activities Report and Appendix 4C
- AGM Chairman's Address and Investor Presentation
- Proteomics receives $2.16 million in R&D tax incentive
- Breakthrough results for endometriosis diagnostic blood test
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories